



Targeted Nanoradiopharmaceuticals as a Molecular Approach for Theranostic Applications

Guest Editors:

Dr. Blanca Ocampo García

Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico

Dr. Enrique Morales-Avila

Facultad de Química, Universidad Autónoma del Estado de México, Paseo Tollocan S/N, Toluca 50120, Mexico

Dr. Laura Melendez-Alafort

Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35138 Padova, Italy

Deadline for manuscript submissions:

closed (31 August 2024)

Message from the Guest Editors

Dear Colleagues,

The field of nanoparticle-based radiopharmaceuticals holds great promise for the diagnosis and treatment of cancer and other diseases. Nanoparticles can be used to deliver radionuclides, cytotoxic drugs, or imaging agents, offering multimodal platforms as integral approaches in the field of nuclear medicine. This Special Issue aims to explore strategies to improve targeting efficiency and to develop methods for encapsulating components that ensure safety and efficacy, in order to propose new approaches for the clinical translation phase.

The sub-topics to be covered within this Special Issue are as follows:

- Radiopharmaceuticals based on organic nanoparticles for combined therapies;
- Radiopharmaceuticals based on metallic nanoparticles for theranostic purposes;
- Radiolabeled nanoparticles for diagnosis or therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma